Clinical Advisors


Professor Fox is a physician with over 25 years’ experience in the pharmaceutical industry with both large and small companies. His industrial positions with large pharma included Glaxo Inc. in North Carolina, where he led the US clinical development of oral, intranasal and subcutaneous sumatriptan (Imitrex®; Imigran®) for migraine and cluster headache. He is now a Visiting Professor at King’s College London. He is a chartered biologist and a Fellow of the Royal College of Physicians as well as its Faculty of Pharmaceutical Medicine; he is also an Adjunct Associate Clinical Professor at the University of California, San Diego. He is on the editorial boards of several journals, and co-edits Principles and Practice of Pharmaceutical Medicine. Professor Fox has published many research papers concerning migraine therapies, pharmacokinetics, and other relevant topics.

Dr Roger Cady is a graduate of the Mayo Medical School and holds board certification in Headache Medicine by the United Council for Neurologic Subspecialties. Dr Cady founded the US-based Headache Care Centre, which comprises a team of specialists in the integrated treatment and care of patients with headache. In particular, Dr Cady has been instrumental in developing the early intervention paradigm for the treatment of acute migraine. He has authored/co-authored over 250 peer-reviewed articles, and in particular, he was the leading author on the paper in JAMA that was the first to describe the therapeutic properties of sumatriptan in a sound, large-scale clinical trial. Dr Cady has written and contributed to numerous books, and co-edited Treating the Headache Patient. He is a member of the Board of Directors for the US National Headache Foundation.


Dr Pullman is a physician with over 25 years’ global experience matured in both large and small pharmaceutical companies, handling small molecules and biotechnology products across all phases of drug development. His industrial positions included Pfizer, Eli Lilly and Sanofi-Aventis where he set strategies and executed operational plans; managed drug discovery and development; supported regulatory approval and commercialisation of many drugs. He has co-authored several scientific papers and contributed to numerous abstracts and presentations for several International Societies. He is a Fellow of the Royal Australian College of Physicians and a speaker in many R&D forums on topics ranging from biomarker development and validation through to clinical development strategies.

Associate Professor Eric Chung is a consultant urological surgeon working in Brisbane Australia and a certified Fellow of the Royal Australasian College of Surgeons (RACS) and Urological Society of Australia and New Zealand (USANZ). He is the current Chair of the Andrology Group in USANZ and serves on many national advisory committees and international organisations. His main areas of interest are urinary dysfunction and reconstructive prosthesis, as well as male sexual and reproductive surgery. He actively runs several Phase 2 and 3 clinical trials, publishes extensively in peer-reviewed journals and book chapters, and has been invited to speak at many national and international meetings.

Dr Ralph is an internationally recognised urological microsurgeon and an Honorary Senior Lecturer at the Institute of Urology and Nephrology, University College London. He also teaches at the Royal College of Surgeons Microsurgery for Andrologists. His main areas of expertise are penile implants, total genital reconstruction, Peyronies disease and male infertility. He is the chairman of the Steering Group, Erectile Dysfunction Alliance, part of the Board of Trustees of the Sexual Dysfunction Association and part of the Nominating Committee of the European Society for Impotence Research. Dr Ralph has published extensively, contributing to book chapters and scientific papers, and regularly speaks at international events.


Dr Nailin Li is an associate professor at the Karolinska Institute in Sweden. He received his medical education in China and doctoral education at Karolinska Institute in Sweden. Dr Li’s main research interests are thrombotic and inflammatory mechanisms in atherosclerosis, platelet angiogenetic activities in arterial remodelling and cancer progression, and clinical evaluation of anti-platelet drugs. He is an internationally recognised researcher in platelet functional studies and platelet-T effector cell interactions. 

Dr Richard Franklin gained his PhD from Surrey University in the UK in Drug Metabolism and Pharmacokinetics and subsequently worked in research and development in the pharmaceutical industry. Dr Franklin has worked for several major drug companies including Glaxo, Wyeth, Sterling Winthrop, & AstraZeneca. Latterly he was head of New Product Innovation at Shire Pharmaceuticals where he is credited with filing over forty patents on potential new drug products.